Cullinan Therapeutics Inc

CGEM

Company Profile

  • Business description

    Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

  • Contact

    One Main Street
    Suite 1350
    CambridgeMA02142
    USA

    T: +1 617 410-4650

    https://www.cullinantherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    109

Stocks News & Analysis

stocks

Stop asking if there’s a stock market bubble. Ask this instead.

Why earnings growth might be more important when assessing frothy market conditions.
stocks

Are negative AI narratives holding this ASX share back?

This company is unlikely to be disrupted by AI
stocks

ASX growth share with attractive dividend

Worries about AI overblown.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,027.907.40-0.08%
CAC 408,367.3317.54-0.21%
DAX 4024,626.8944.33-0.18%
Dow JONES (US)52,182.74306.630.59%
FTSE 10010,484.2223.80-0.23%
HKSE23,001.5625.12-0.11%
NASDAQ25,820.14522.532.07%
Nikkei 22570,125.17657.060.95%
NZX 50 Index13,627.6182.050.61%
S&P 5007,440.4386.411.18%
S&P/ASX 2008,827.104.40-0.05%
SSE Composite Index4,059.6614.24-0.35%

Market Movers